



an Open Access Journal by MDPI

Pharmacotherapy for Colorectal Cancer

Guest Editor:

Dr. Kamila Środa-Pomianek

Department of Biophysics and
Neurosciences, Wrocław Medical
University, 50-367 Wrocław,
Poland

Deadline for manuscript
submissions:

closed (30 November 2022)

Message from the Guest Editor

Colorectal carcinoma is one of the most frequent malignant cancers of the gastrointestinal tract. Unfortunately, in the process of defending the malignant cells against the activity of cytotoxic drugs used in chemotherapy, many signal pathways are involved, which leads to the insufficient effectiveness of the pharmacological treatment. New compounds that could manifest potential anticancer activity are therefore constantly studied. Because of the multifactorial character of cancers, searching for an effective therapeutic substance is oriented towards the so-called multifunctional drugs, which at the same time affect several biological targets.

This Special Issue focused on pharmacotherapy for colorectal cancer and the implementation of combination therapies that entail the combined use of two or more cancer-cell-growth inhibitors. The simultaneous use of many active substances can increase the risk of side-effects, but the skillful use of the interactions that occur among them allows increasing their effectiveness and the safety of the therapy.



mdpi.com/si/123757

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com